United-Guardian, Inc. — Q3 2016 Form 10-Q
Reporting period: Three and nine months ended September 30, 2016. United-Guardian develops, manufactures, and markets personal care, pharmaceutical, medical, and specialty industrial products. Its LUBRAJEL personal-care ingredients are a key product line; marketing partner Ashland Specialty Ingredients (ASI) is its largest customer/partner.
Financial performance
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Net sales | $3.46 million | $3.62 million | $7.86 million | $12.12 million |
| Income from operations | $1.24 million | $1.69 million | $2.47 million | $5.88 million |
| Net income | $0.90 million | $1.22 million | $1.83 million | $4.19 million |
| Diluted EPS | $0.20 | $0.26 | $0.40 | $0.91 |
| Operating margin | 36.0% | 46.8% | 31.5% | 48.5% |
| Gross margin | 53.9% | 63.2% | 55.5% | 63.6% |
Q3 sales declined 4.5% year over year; nine-month sales fell 35.1%. Net income decreased about 26% in Q3 and 56% for the nine-month period. The effective tax rate was approximately 31% and management expected it to remain consistent for 2016.
Cash flow, nine months: Operating cash flow was $1.67 million, down from $4.11 million. Investing activities used $0.12 million, versus $2.61 million used in 2015, mainly reflecting lower purchases of marketable securities. Dividends used $1.60 million, versus $2.30 million; the per-share dividend declined from $0.50 to $0.35. Cash decreased $53,480 to $1.03 million.
Balance sheet at September 30, 2016: Cash and equivalents were $1.03 million and marketable securities were $11.07 million. Working capital was $14.13 million, up $0.60 million from year-end 2015; the current ratio was 10.7:1 versus 14.7:1. Total assets were $16.74 million and stockholders’ equity was $15.04 million. No debt is reported on the balance sheet. Management said working capital should support operations for at least 12 months and anticipated no significant capital expenditures for the remainder of 2016.
Material changes and management commentary
- Personal-care sales fell 36.0% in Q3 and 59.8% year to date. ASI sales declined 43.6% and 67.8%, respectively, primarily because ASI worked down excess LUBRAJEL inventory after overly optimistic customer forecasts in China and a separate Chinese regulatory issue temporarily interrupted production of products containing another ingredient. ASI’s excess inventory had returned to an appropriate level, shipments to China resumed in September, and ASI anticipated regular monthly orders.
- Pharmaceutical sales rose 130.8% in Q3 and 75.0% year to date, mainly due to RENACIDIN, including introduction of a 30 mL single-dose form in April 2016. Medical-product sales also increased, while industrial and miscellaneous sales were approximately flat.
- Cost of sales rose to 46.1% of sales in Q3 and 44.5% year to date, primarily because RENACIDIN, manufactured by a third party, carries lower margins than many other products. Management also cited competition from lower-priced imitations, a strong U.S. dollar, and weak European economic conditions as pressures on personal-care sales and margins; selective price reductions may continue.
- Management expects operating expenses to remain relatively constant and intends to continue using cash for dividends, marketable securities, and other opportunities considered beneficial to the company and shareholders. No formal earnings or revenue guidance was provided.
Risks, contingencies, and controls
The filing identifies risks including product-development and market-acceptance challenges, competition, product quality, intellectual-property changes, economic and industry conditions, regulatory changes, interest rates, and securities-market conditions. The company reported no legal proceedings, off-balance-sheet arrangements, or material changes in internal control over financial reporting; management deemed disclosure controls effective. Commitments and contingencies are noted, but no specific contingent amount is stated in the supplied filing text.
Key facts for investors to verify
- Whether ASI’s resumed China orders develop into sustained monthly purchases and how quickly its inventory normalizes.
- Whether the sharp year-to-date sales and earnings declines stabilize, particularly in personal-care products.
- How the growing mix of lower-margin RENACIDIN sales and competitive pricing affects gross margins.
- Dividend sustainability relative to operating cash generation and the company’s investment portfolio.
- Marketable-securities values and related unrealized gains, which affect comprehensive income and equity.